Today: 16 July 2026
UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny

UnitedHealth Stock Slides Again as April Earnings Loom, Putting UNH Valuation Under New Scrutiny

NEW YORK, March 27, 2026, 15:55 EDT

UnitedHealth Group shares dropped over 4% Friday, deepening losses that had already triggered fresh talk about valuation and next week’s earnings after sinking 1.6% earlier in the week. The stock changed hands at $257.04 by mid-afternoon in New York.

UnitedHealth now stands out as the bellwether for U.S. health-insurance stocks, especially after that nearly 20% drop back in January. With first-quarter earnings due April 21, Wall Street is watching closely for any indication that those elevated medical costs and persistent headwinds in Medicare Advantage — the privately managed Medicare plans targeting older adults — might finally be receding.

Shares of Humana, Elevance, and Cigna each lost ground Friday, dropping anywhere from 2.9% to 3.4%. The Health Care Select Sector SPDR ETF shed 1.5% as well. UnitedHealth wasn’t the only one under pressure.

Over the last day, fresh talk has centered on two things: is the stock finally cheap enough after the recent selloff, and will earnings keep sliding next quarter? According to a Barchart preview posted late Thursday, Wall Street is looking for first-quarter earnings of $6.62 per share, which would be an 8.1% drop from the same period a year ago. The company has come in above forecasts twice in the past four quarters and fallen short twice.

The argument over valuation is still hanging around. Barchart points out the stock continues to hold a Moderate Buy consensus and an average target price of $359.04—about 40% higher than where it closed on Friday. That’s despite several months of target reductions across the sector.

Those January comments are still weighing on the stock. UnitedHealth at the time put 2026 revenue above $439 billion, pointing to a 2% drop from 2025. The insurer also called for adjusted earnings topping $17.75 a share. As for the medical care ratio — essentially the portion of premiums going toward care — UnitedHealth guided to about 88.8% while it works to reset pricing and defend margins.

Back in January, Chief Executive Stephen Hemsley claimed the company “confronted challenges directly” and wrapped up 2025 “as a much stronger company.” But James Harlow, senior vice president at Novare Capital Management, flagged the Medicare proposal released that month, saying it “starts to bring in worries about 2027 earnings growth.” UnitedHealth Group

Caution isn’t just limited to a single company. “There’s a bit of a ‘show me’ story here” for health insurers on pricing’s ability to actually bring margins back, said Allen Coker, senior analyst at Manning & Napier, after Elevance offered a notably cautious outlook for 2026. Reuters

UnitedHealth keeps churning out updates. On Thursday, UnitedHealthcare introduced Avery, an AI assistant. Dan Kueter, who runs the commercial side, says folks “want care to be easier to use and tailored to their personal needs.” It’s a new pitch for the company, but Friday’s action made it clear—investors are eyeing claim trends, not just the latest tech rollout. UnitedHealth Group

The quarter could flip sentiment fast. Stronger April utilization numbers and any signs repricing efforts are gaining traction might help close the stock’s gap to consensus targets. But if costs don’t come down—or if management cuts guidance once more—then Friday’s selloff could start to look less like a blip and more like the start of a tougher stretch.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Brookfield Asset Management (TSX:BAM) Trades Above Intrinsic Value as AI Bets Raise Risks
    July 16, 2026, 4:54 AM EDT. Brookfield Asset Management (TSX:BAM) stock is up 72.4% over three years, but now sits about 29% higher than its intrinsic value based on an Excess Returns model. The model pegs fair value at CA$53.37 per share, lower than where the stock is currently trading, hinting valuation is stretched. Traditional multiples don't look demanding, but Brookfield's push into AI-driven data center infrastructure means larger capital needs and more risk on execution. The stock has dropped 12.1% in the past year, lagging peers. Simply Wall St's valuation scorecard flags missed checks, with fundamentals and growth outlook not supporting the price as a bargain.
XRP Price Today Drops to $1.36 as Oil Spike and Iran War Jitters Hit Crypto
Previous Story

XRP Price Today Drops to $1.36 as Oil Spike and Iran War Jitters Hit Crypto

Ciena Corporation Stock Swings After Insider Sale Filing as AI Networking Boom Gets Tested
Next Story

Ciena Corporation Stock Swings After Insider Sale Filing as AI Networking Boom Gets Tested

Go toTop